Visualization of network target crosstalk optimizes drug synergism in myocardial ischemia

PLoS One. 2014 Feb 5;9(2):e88137. doi: 10.1371/journal.pone.0088137. eCollection 2014.

Abstract

Numerous drugs and compounds have been validated as protecting against myocardial ischemia (MI), a leading cause of heart failure; however, synergistic possibilities among them have not been systematically explored. Thus, there appears to be significant room for optimization in the field of drug combination therapy for MI. Here, we propose an easy approach for the identification and optimization of MI-related synergistic drug combinations via visualization of the crosstalk between networks of drug targets corresponding to different drugs (each drug has a unique network of targets). As an example, in the present study, 28 target crosstalk networks (TCNs) of random pairwise combinations of 8 MI-related drugs (curcumin, capsaicin, celecoxib, raloxifene, silibinin, sulforaphane, tacrolimus, and tamoxifen) were established to illustrate the proposed method. The TCNs revealed a high likelihood of synergy between curcumin and the other drugs, which was confirmed by in vitro experiments. Further drug combination optimization showed a synergistic protective effect of curcumin, celecoxib, and sililinin in combination against H₂O₂-induced ischemic injury of cardiomyocytes at a relatively low concentration of 500 nM. This result is in agreement with the earlier finding of a denser and modular functional crosstalk between their networks of targets in the regulation of cell apoptosis. Our study offers a simple approach to rapidly search for and optimize potent synergistic drug combinations, which can be used for identifying better MI therapeutic strategies. Some new light was also shed on the characteristic features of drug synergy, suggesting that it is possible to apply this method to other complex human diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Antioxidants / pharmacology
  • Celecoxib
  • Cells, Cultured
  • Curcumin / pharmacology*
  • Cyclooxygenase 2 Inhibitors / pharmacology
  • Drug Synergism*
  • Drug Therapy, Combination / methods
  • Humans
  • Molecular Targeted Therapy / methods
  • Myocardial Ischemia / drug therapy*
  • Myocardial Ischemia / metabolism
  • Myocardial Ischemia / pathology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Pyrazoles / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Silybin
  • Silymarin / pharmacology
  • Sulfonamides / pharmacology*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antioxidants
  • Cyclooxygenase 2 Inhibitors
  • Pyrazoles
  • Silymarin
  • Sulfonamides
  • Silybin
  • Curcumin
  • Celecoxib

Grants and funding

This work is supported by a grant from Department of Education of Heilongjiang Province of China (No. 11533042) and the Department of Technology of Heilongjiang Province of China (No. D201020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.